These trials have investigated a wide range of PI3K/AKT inhibitors as monotherapy or in combination with other anticancer agents across different cancer types, including breast cancer, colorectal cancer, lung cancer, and melanoma. This evidence concerns the gene PIK3CA and breast carcinoma.